254877-67-3

Basic information

• Product Name: Ataciguat
• Synonyms: 5-Chloro-2-[[(5-chloro-2-thienyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl)phenyl]benzamide;Ataciguat;HMR 1766
• CAS NO: 254877-67-3
• Molecular Formula: C21H19Cl2N3O6S3
• Molecular Weight: 576.5
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;Pharmaceuticals, Intermediates & Fine Chemicals, Sulfur & Selenium Compounds
• Mol File: 254877-67-3.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Density: 1.613 g/cm³
• Refractive Index: 1.684
• PKA: 5.70±0.50(Predicted)
• CAS DataBase Reference: Ataciguat(CAS DataBase Reference)
• NIST Chemistry Reference: Ataciguat(254877-67-3)
• EPA Substance Registry System: Ataciguat(254877-67-3)

Safety Data

• Hazardous Substances Data: 254877-67-3(Hazardous Substances Data)

Usage

Uses

Ataciguat, formerly referred to as HMR-1766, a novel anthranilic acid derivative, belongs to a new structural class of sGC activators capable of activating the oxidized form of sGC. Ataciguat has been shown to improve endothelial function and to reduce platelet activation in exptl. diabetes. Chronic regular treatment with sGC activators such as ataciguat could therefore eventually constitute an effective therapy targeting deficient NO/cGMP signaling in hypertension, peripheral and coronary artery disease, heart failure, thrombosis and erectile dysfunction.

InChI:InChI=1/C21H19Cl2N3O6S3/c22-14-1-6-18(25-34(28,29)20-8-7-19(23)33-20)17(13-14)21(27)24-15-2-4-16(5-3-15)35(30,31)26-9-11-32-12-10-26/h1-8,13,25H,9-12H2,(H,24,27)

Upstream product

• 254877-58-2 2-Amino-5-chloro-N-(4-(morpholine-4-sulfonyl)-phenyl)-benzamide 
• 2766-74-7 5-chlorothien-2-ylsulfonyl chloride 

Relevant articles and documents

SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM

The present invention relates to compounds of the formula I wherein A1, A2, R1, R2, R3, X and n are as defined in the claims, which are valuable pharmaceutically active compounds for the therapy and prophylaxis of diseases, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I are capable of modulating the body’s production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the formula I